Sorry, your browser does not support JavaScript!
Find a Treatment Center
Investor Relations
Contact Us
About Us
Our Mission
Our Story
Therapeutic Areas
Leadership
Kite Locations
Cell Therapy
Our Cell Therapy Technology
Our Therapies
Pipeline
Trials & Expanded Access
Clinical Trial Diversity
External Research Program (ERP)
Patient Resources
Patient Stories
Our Authorized Treatment Centers
Kite Konnect
Newsroom
Newsroom
Press Releases
Company Statements
Media Kit
Careers
Careers
Veteran Careers
Early Talent Programs
Culture & Benefits
Utility
Investor Relations
Contact Us
Kite Konnect®
Contact Us
Find a Treatment Center
Investor Relations
Newsroom
Recent Press Releases
June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 03, 2024
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Recent Company Statements
October 16, 2024
Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations
Explore More
Media Inquiries
Gilead Newsroom
Twitter Feed